OmniAb Inc. reported its third‑quarter 2025 results on November 4, 2025, posting revenue of $2.2 million—down 47% from $4.2 million in the same quarter a year earlier—while the company recorded a net loss of $16.5 million, or $0.14 per share, exactly matching the consensus estimate of $-0.14. The revenue shortfall was driven primarily by the completion of a handful of small‑molecule ion‑channel programs, which removed milestone and service revenue that had been earned in the prior year. CFO Kurt Gustafson noted that the loss of these milestones, coupled with a shift of expected 2025 milestones to 2026, explains the decline in service revenue and the overall revenue miss.
When compared to the nine‑month period ending September 30, 2025, OmniAb’s revenue fell from $15.6 million in 2024 to $10.3 million in 2025, while the net loss widened from $49.0 million to $50.6 million. The year‑over‑year decline in revenue and the modest increase in net loss underscore the company’s ongoing revenue headwinds, even as it maintains a flat earnings‑per‑share loss, indicating that cost controls have kept the loss from expanding further.
Guidance for the remainder of 2025 has been revised downward. Management now expects total revenue between $18 million and $22 million, a reduction from the prior $20 million to $25 million range. Operating expenses are projected at $82 million to $86 million, and cash balances are expected to end the year between $52 million and $56 million. The guidance cut reflects the anticipated shift of milestone revenue to 2026, lower service revenue, and the company’s focus on maintaining a lean operating structure while investing in its platform.
CEO Matthew Foehr emphasized that the company’s strategic initiatives remain on track, citing the successful $30 million private placement that strengthened the balance sheet and the upcoming launch of OmniUltra™ in December 2025. He highlighted that new program additions in 2025 have outpaced last year’s pipeline, reinforcing the long‑term value of the partner base. CFO Gustafson added that the company has identified further operating efficiencies and is updating guidance to reflect the new milestone timeline.
In aftermarket trading, OmniAb’s shares rose 2.36 %, reflecting investor optimism about the company’s strategic direction. The market reaction was driven by confidence in the upcoming OmniUltra™ platform, the expansion of the partner pipeline, and the strengthened balance sheet from the private placement, rather than the immediate revenue miss.
Overall, the results illustrate a company that is managing costs effectively enough to keep its earnings‑per‑share loss flat, but that faces significant revenue headwinds due to milestone shifts and program completions. The downward guidance signals caution about near‑term revenue growth, while the focus on platform development and strategic partnerships positions OmniAb for longer‑term value creation.
revised_sentiment_rating
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.